Exagen (XGN) Q1 2025 Earnings Call May 05, 2025 08:30 AM ET Speaker0 Greetings, and welcome to the Exagen Inc. First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Ryan Douglas, Investor Relations for Exagen Inc. Thank you. You may begin. Speaker1 Good morning, and th ...

With a nearly 39% stock price decline this week, according to data compiled by S&P Global Market Intelligence, GeneDx Holdings (WGS 7.80%) was deep in the doghouse with investors. They traded out of the stock following the company's latest earnings release and a subsequent round of analyst price target cuts.A victim of high expectationsWhat's interesting about GeneDx's tumble is that its first-quarter performance was, on the surface, rather good. The figures released Wednesday revealed the DNA testing compa ...

Core Insights - Fortive Corporation reported first-quarter 2025 adjusted EPS of 85 cents, in line with estimates, with a year-over-year increase of 2.4% [1] - Revenues declined 3.3% year over year to $1.47 billion, missing estimates by 1.2%, with core revenues down 1.7% [1] - The decline in revenues was primarily due to weakness in the Precision Technologies segment, partially offset by growth in Intelligent Operating Solutions and Advanced Healthcare Solutions [1] Financial Performance - Intelligent Operating Solutions generated revenues of $671.4 million, contributing 45.5% to total revenues, up 0.9% year over year [5] - Precision Technologies reported revenues of $500.6 million, down 10.5% year over year, affected by tough comparisons and customer order delays [6] - Advanced Healthcare Solutions achieved revenues of $302.2 million, up 0.8% year over year [6] - Gross profit decreased 3.1% to $880.9 million, with an adjusted operating margin of 25.3%, an increase of 20 basis points year over year [7] Strategic Developments - Fortive announced plans to separate its Precision Technologies business into an independent company, Ralliant, expected to be completed by the end of Q2 2025 [2] - The separation aims to create two focused companies, with Fortive concentrating on IOS and AHS, while Ralliant will specialize in precision instruments [2] - Management revised 2025 guidance due to delayed recovery in Precision Technologies and global tariffs, expecting adjusted diluted EPS to be $3.80 to $4 [3][10] Outlook - For Q2 2025, core performance in Precision Technologies is expected to decline, while the "New Fortive" is anticipated to maintain steady growth [12] - Adjusted EPS for Q2 is projected to be between 85 cents and 90 cents, with the Zacks Consensus Estimate at 99 cents [12] - The company is maintaining its core growth outlook for the "New Fortive," despite potential subdued demand in certain areas [11]

Core Viewpoint - Viavi Solutions Inc. reported strong third-quarter fiscal 2025 results, with revenues and net income exceeding expectations, driven by growth in the Network Enablement and Service Enablement segments, although macroeconomic challenges pose concerns for future spending [1][2]. Financial Performance - Net income on a GAAP basis was $19.5 million or 9 cents per share, a significant improvement from a net loss of $24.6 million or 11 cents per share in the prior year [2]. - Non-GAAP net income rose to $33.9 million or 15 cents per share, up from $13.2 million or 6 cents per share year-over-year, surpassing the Zacks Consensus Estimate by 3 cents [2]. Revenue Breakdown - Quarterly revenues reached $284.8 million, reflecting a 15.8% year-over-year increase, exceeding the Zacks Consensus Estimate of $282 million [3]. - The Network Enablement segment generated $188 million in net sales, a 23.9% increase from $151.7 million in the previous year, driven by strong demand from service providers and network equipment manufacturers [3]. - Service Enablement segment revenues were $20.2 million, up 11.6% year-over-year, supported by healthy demand trends [4]. - Optical Security and Performance Products revenues slightly increased to $76.6 million from $76.2 million, primarily due to strength in anti-counterfeiting products [4]. - Revenue contributions from different regions included $108.1 million from America, $100.7 million from Asia-Pacific, and $76 million from EMEA, showing respective increases from the previous year [5]. Margins and Operating Performance - Non-GAAP gross margin improved to 60%, up 210 basis points year-over-year, with the NE segment's gross margin at 63.4%, an increase of 190 basis points [6]. - Total non-GAAP operating margin increased by 740 basis points year-over-year to 16.7%, with the NSE business operating margin rising to 10.4% [7]. Cash Flow and Liquidity - The company generated $7.8 million in cash from operating activities during the quarter, a decrease from $19.5 million in the prior year [8]. - As of March 29, 2025, Viavi had $374.2 million in cash and cash equivalents and $396.1 million in long-term debt [8]. Outlook - For the fourth quarter of fiscal 2025, management anticipates revenues between $278 million and $290 million, with non-GAAP earnings per share expected to be between 10 cents and 13 cents [10]. - Projected revenues for the NSE business are between $203 million and $213 million, while the OSP segment is expected to generate revenues between $75 million and $77 million [10].

inTEST (INTT) Q1 2025 Earnings Call May 02, 2025 08:30 AM ET Company Participants Shawn Southard - Investor RelationsRichard Grant - President & CEODuncan Gilmour - CFO, Treasurer & SecretaryJaeson Schmidt - Director of Research Conference Call Participants Richard Ryan - Vice President, Senior Research AnalystTed Jackson - MD & Senior Research Analyst Operator Greetings and welcome to the Intest Corporation First Quarter twenty twenty five Financial Results. At this time, all participants are in a listen o ...

Financial Data and Key Metrics Changes - Revenue in Q1 2025 totaled $73.5 million, down from $76.2 million in Q4 2024, with negligible revenue from COVID-19 testing [21] - GAAP gross margin was 38.6%, while non-GAAP gross margin was 41%, showing year-over-year improvement due to operational efficiencies [21][22] - Total GAAP operating expenses were $48.1 million, slightly up from $48 million in Q4 2024, with non-GAAP operating expenses remaining flat at $37.4 million [22] - Adjusted EBITDA loss for Q1 was approximately $2.9 million, an improvement from a loss of $3.2 million in Q1 2024 [23] - The company ended Q1 with approximately $814.6 million in cash, cash equivalents, restricted cash, and marketable securities [23] Business Line Data and Key Metrics Changes - Precision diagnostics revenue increased by $6.7 million or 17.8% year-over-year, while anatomic pathology revenue rose by $2.2 million or 9.5% year-over-year [13] - Biopharma services revenue grew by $1.4 million or 51.3% year-over-year, although it experienced a sequential decline of 33.7% due to contract timing [14] - The growth in precision diagnostics was driven by reproductive health services and expanded carrier screening, with new client wins contributing significantly [14][15] Market Data and Key Metrics Changes - The company is seeing significant usage from new VA hospitals and positive momentum from partnerships, particularly with Foundation Medicine [14][15] - The biopharma services business is expected to experience variability quarter-to-quarter, but the company anticipates continued demand due to improved product offerings [19] Company Strategy and Development Direction - The company is focused on expanding its laboratory services and therapeutic development pipeline, with ongoing clinical trials for candidates FID-seven and FID-twenty two [10][11] - Investments in digital pathology and AI are expected to enhance operational efficiency and quality [18] - The company is evaluating potential M&A opportunities to enhance its distribution network and technology deployment [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the fundamentals in 2025, with expectations for core revenue to reach approximately $310 million, representing a 10% year-over-year growth [24] - Non-GAAP gross margins are expected to slightly exceed 40% for the full year, with anticipated cash burn for therapeutics development around $25 million [26] - The company aims to manage spending while focusing on capital allocation to support growth initiatives [27] Other Important Information - The company has repurchased approximately 646,000 shares at a cost of $10.9 million since the beginning of 2025, with a total of $110.4 million spent since the inception of the repurchase program [23][27] - The SEC investigation concluded with no enforcement action recommended, resulting in a reversal of a previously accrued liability of $1 million [22] Q&A Session Summary Question: Why not raise the full year guidance despite good momentum? - Management prefers to be more comfortable before adjusting guidance, aiming for considerable changes rather than minor adjustments [30][31] Question: How much of Q1 results came from new accounts in precision diagnostics? - The strong performance was driven by both existing clients and new client wins, with ongoing onboarding processes for larger clients [32][34] Question: Expectations for stock buybacks and M&A potential in 2025? - The company is actively deploying capital for stock buybacks and evaluating M&A options to enhance distribution and technology [36][37] Question: Expected penetration rate for FID-one hundred seven and its market potential? - The initial focus is on head and neck cancer, with potential for broader applications post-trial [39] Question: Thoughts on capital deployment for expanding sales and marketing? - Sales and marketing expenses are expected to increase as the company hires new personnel across various divisions [41][42]

Core Viewpoint - AMETEK, Inc. reported mixed financial results for Q1 2025, with earnings per share exceeding estimates while revenue slightly missed expectations, indicating challenges in its largest segment but some growth in another segment [1][3][7]. Financial Performance - Non-GAAP earnings for Q1 2025 were $1.75 per share, surpassing the Zacks Consensus Estimate by 3.6% and reflecting a 7% year-over-year increase [1]. - Total revenue for the quarter was $1.73 billion, which fell short of the Zacks Consensus Estimate by 0.51% and represented a 0.2% decline year-over-year [1][3]. - Operating income increased by 2% year-over-year to $454.8 million, with an operating margin expansion of 60 basis points [4]. Segment Performance - The EIG segment, accounting for 65.9% of total revenue, reported sales of $1.14 billion, down 1% from the previous year and missing the consensus estimate of $1.15 billion [3]. - The EMG segment, which makes up 34.1% of total revenues, saw sales of $588.3 million, up 2% year-over-year and exceeding the consensus estimate of $580 million [3]. Cash Flow and Balance Sheet - As of March 31, 2025, AMETEK had cash and cash equivalents of $399 million, an increase from $373.9 million in the previous quarter [5]. - Operating cash flow for Q1 was $417.5 million, with free cash flow at $394.5 million, indicating a free cash flow to net income conversion rate of 112% [6]. Guidance - For 2025, AMETEK expects overall sales to increase in low single digits compared to 2024, with the Zacks Consensus Estimate at $7.17 billion, reflecting a year-over-year increase of 3.4% [7]. - The company reiterated its adjusted earnings per share guidance in the range of $7.02-$7.18, suggesting a 3-5% increase, with the consensus estimate at $7.13 per share, indicating a year-over-year increase of 4.4% [7].

Itron (ITRI) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of $1.30 per share. This compares to earnings of $1.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.92%. A quarter ago, it was expected that this energy and water meter company would post earnings of $1.05 per share when it actually produced earnings of $1.35, delivering a surprise of 28.57%.Over the last four quarters, ...

Fortive (FTV) came out with quarterly earnings of $0.85 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.83 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this industrial conglomerate would post earnings of $1.12 per share when it actually produced earnings of $1.17, delivering a surprise of 4.46%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Fortive, which belongs ...

May 1, 2025 © 2025 Sotera Health Company | All Rights Reserved. Safeguarding Global Health® First-Quarter 2025 Earnings Results Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms "Sotera Health," "Company," "we," "us," and "our" in this document refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This release contains forward- looking ...